Coronavirus

11
Pipeline Programs
9
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
3
1
3
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
375%
Small Molecule
125%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

C
CureVacGermany - Tübingen
4 programs
1
3
CVnCoV VaccinePhase 3Vaccine1 trial
CVnCoV VaccinePhase 3Vaccine1 trial
CVnCoV VaccinePhase 3Vaccine1 trial
CVnCoV 6 μgPhase 21 trial
Active Trials
NCT04515147CompletedEst. Feb 2022
NCT04860258TerminatedEst. Sep 2021
NCT04838847WithdrawnEst. Sep 2022
+1 more trials
Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
1
bamlanivimab 7000mgPhase 2/3
Bristol Myers Squibb
1 program
1
bamlanivimab 7000mgPhase 2/3
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
bamlanivimab 7000mgPhase 2/3
Gylden Pharma
Gylden PharmaUK - Abingdon
2 programs
1
1
PepGNP-COVID19Phase 1/21 trial
LD Vehicle-GNPPhase 11 trial
Active Trials
NCT05113862Completed26Est. Sep 2022
NCT05633446Not Yet Recruiting110Est. Dec 2026
Celularity
CelularityFLORHAM PARK, NJ
1 program
1
CYNK-001Phase 1/21 trial
Active Trials
NCT04365101UnknownEst. Jun 2022
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
RuxolitinibPhase 1/2Small Molecule
Alliance Pharmaceuticals
1 program
Observation of patients with known, suspected, or at risk for COVID-19 infectionN/A1 trial
Active Trials
NCT04321811Completed5,000Est. Mar 2021
Aytu BioPharma
Aytu BioPharmaDENVER, CO
1 program
UV Light TreatmentN/A1 trial
Active Trials
NCT04572399CompletedEst. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CureVacCVnCoV Vaccine
CureVacCVnCoV Vaccine
CureVacCVnCoV Vaccine
CureVacCVnCoV 6 μg
Gylden PharmaPepGNP-COVID19
CelularityCYNK-001
Gylden PharmaLD Vehicle-GNP
Aytu BioPharmaUV Light Treatment
Alliance PharmaceuticalsObservation of patients with known, suspected, or at risk for COVID-19 infection

Clinical Trials (9)

Total enrollment: 5,136 patients across 9 trials

NCT04838847CureVacCVnCoV Vaccine

A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19

Start: Oct 2021Est. completion: Sep 2022
Phase 3Withdrawn
NCT04860258CureVacCVnCoV Vaccine

COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

Start: Apr 2021Est. completion: Sep 2021
Phase 3Terminated
NCT04674189CureVacCVnCoV Vaccine

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Start: Dec 2020Est. completion: Jun 2022
Phase 3Completed
NCT04515147CureVacCVnCoV 6 μg

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Start: Sep 2020Est. completion: Feb 2022
Phase 2Completed
NCT05633446Gylden PharmaPepGNP-COVID19

Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Start: Sep 2025Est. completion: Dec 2026110 patients
Phase 1/2Not Yet Recruiting
NCT04365101CelularityCYNK-001

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Start: May 2020Est. completion: Jun 2022
Phase 1/2Unknown
NCT05113862Gylden PharmaLD Vehicle-GNP

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Start: Jan 2022Est. completion: Sep 202226 patients
Phase 1Completed
NCT04572399Aytu BioPharmaUV Light Treatment

UVA Light Device to Treat COVID-19

Start: Oct 2020Est. completion: Dec 2020
N/ACompleted
NCT04321811Alliance PharmaceuticalsObservation of patients with known, suspected, or at risk for COVID-19 infection

Behavior, Environment And Treatments for Covid-19

Start: Mar 2020Est. completion: Mar 20215,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
9 companies competing in this space